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Abstract
Background: Patients with advanced (incurable) tumours usually experience a diverse burden of
symptoms. Although many symptom assessment instruments are available, we examined whether
these addressed tumour-related symptoms.
Methods:  We reviewed existing symptom assessment instruments and found a number of
deficiencies such as instruments being too long or burdensome, too short, or measuring quality of
life rather than tumour-related symptoms. Others focused on emotional, rather than physical
symptoms. Therefore, we decided to devise a new symptom instrument. A list of 20 symptoms
common in patients with advanced tumours generated from the literature and existing instruments,
was ranked according to prevalence by 202 Australian clinicians. Following clinicians' responses, the
list was revised and two severity assessment scales (functional severity and distress severity) added.
The resultant 18-item list was assessed in 44 outpatients with advanced tumours.
Results: Patient responses indicated that a shorter questionnaire of 11 items, reflecting three main
symptom clusters, provided a good representation of physical symptoms. An additional symptom
that is an important predictor of survival was added, making a 12-item questionnaire, which was
entitled "The Canberra Symptom Scorecard" (CSS). For symptom severity, the distress severity
scale was more appropriate than the functional severity scale.
Conclusion: The CSS focuses on tumour-related physical symptoms. It is about to be assessed in
patients with advanced tumours receiving palliative treatments, when it will also be validated against
existing instruments.
Background
Few metastatic tumours are curable and the principal aim
of treatment is to improve patients' tumour-related symp-
toms to maximise quality of life (QoL). A number of QoL
and symptom assessment instruments [1-15] has been
developed for use in patients with advanced tumours
(Table 1 – see additional file 1). These are usually com-
pleted by the patient, and predominantly are used as out-
come measures in clinical trials [15-22]. In clinical
practice, clinicians usually assess symptoms in a less
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formal fashion, although there are instruments, such as
the Edmonton symptom assessment system (ESAS) [21]
that are used on a regular basis, in some practices.
Most appraisals of existing symptom assessment instru-
ments have concluded that they are relevant and accepta-
ble for QoL assessment in patients with advanced
tumours [1,9-13,15,16,18,20-25]. On the other hand, a
number of limitations has been identified in existing
instruments: many of the instruments are too lengthy to
be administered regularly (e.g. the adapted symptom dis-
tress scale (ASDS), the functional assessment of cancer
therapy scale-general (FACT-G), the McGill quality of life
questionnaire (MQOL), the Memorial symptom assess-
ment scale (MSAS), and the Rotterdam symptom checklist
(RSCL)) [6,7,11,12,14] or they provide only limited ben-
efit in the assessment of symptoms in the more seriously
ill patients (e.g. ESAS, RSCL, the patient evaluated prob-
lem scores (PEPS)) [20,21,24]. Further, the instrument
may fail to measure the patient's experience (e.g. the sup-
port team assessment schedule (STAS)) [9,10], or the ref-
erence period is either absent or too short (MQOL)
[22,25]. Those that measure QoL rather than tumour-
related symptoms (e.g. FACT-G, the EORTC quality of life
questionnaire (QLQ-C30), MQOL) tend to be too broad
and less relevant for measuring symptoms [7,11]. In con-
trast, other instruments are too short to be comprehensive
(e.g. PEPS) [24], or there is doubt that the coverage of
symptoms is appropriate (e.g. the M.D. Anderson symp-
tom inventory (MDASI)) [13]. There is also inconsistency
between the severity assessment scales used by different
instruments, typically either indicating the impairment of
functioning (e.g. FACT-G) [7], or the distress caused by a
symptom or symptoms (e.g. ESAS, the symptom distress
scale (SDS), modified SDS, ASDS, MQOL) [1,3-6,11], or
both (e.g. MDASI, RSCL) [13,14].
Because of these limitations, we decided to investigate the
optimal coverage of symptoms necessary and the most
appropriate severity assessment scale in an effort to iden-
tify an optimal symptom assessment instrument for
patients with advanced tumours.
In this study, we explored patient and clinician prevalence
rankings of tumour-related symptoms in outpatients with
advanced tumours. Based on these relationships, we iden-
tified the shortest list of symptoms that covered the major
clusters of tumour-related symptoms best for this popula-
tion. We also examined two different severity assessment
scales for each symptom to assess variation between the
scales, and whether more than one type of severity assess-
ment scale was needed.
Methods
The common symptoms in advanced tumours
A list of 33 of the most frequent symptoms experienced by
patients with advanced tumours was compiled from a
review of the literature [26,27] and existing symptom
assessment instruments. After interviews on symptom
prevalence with 14 patients with advanced tumours and
with three clinicians involved in the management of
patients with advanced tumours from The Canberra Hos-
pital, the list was reduced to 20 symptoms.
Assessing the initial 20-item symptom list
The 20-item symptom list was circulated to Medical
Oncologists, Radiation Oncologists and Palliative Care
Physicians around Australia who were invited to com-
ment on the 20 symptoms included in the list and to rank
the symptoms according to prevalence in patients with
advanced tumours. Clinicians were identified by their
membership of the special society for their subspecialty.
Two versions of the symptom list were generated using
different ordering and one of the versions was randomly
attached to each invitation. Space was also made available
for clinicians to add up to three additional symptoms that
they believed should also be included. Of the 522 clini-
cians contacted, 202 (38.7%) responded, with 184 clini-
cians ranking all 20 symptoms. These responses were
analysed and the number of symptoms included in the list
was reduced further.
Assessing the revised symptom list in patients with 
advanced tumours
Between April and June 2001, the revised symptom list
was assessed in 44 outpatients with advanced tumours
attending the Medical Oncology Unit or the Department
of Radiation Oncology, at the Canberra Hospital. The
oncologists were given details of the study and enrolled
eligible patients in a sequential fashion. Eligibility criteria
required that patients were aged 18 years or older, had an
advanced (incurable) tumour, and were receiving pallia-
tive treatment(s). In addition, patients were required to
have an ECOG performance status of 0–3, adequate Eng-
lish language skills to complete the questionnaire, no seri-
ous concomitant medical or psychiatric condition, and to
give written informed consent to participate. The majority
of patients completed the questionnaire on their own, but
assistance was available from the research staff, if
required.
Details of the 44 outpatients who participated are shown
in Table 1. The majority was male, the median age was 60
years (range 39–81 years) and the patients had a variety of
incurable solid tumours or lymphoma. Of the 44 patients,
eight remain alive, but the rest have died. The median sur-
vival for the group was 39 weeks (range 3 – 128+ weeks).
Enrolment was restricted to 44 patients as post hoc powerBMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/32
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calculations indicated that the sample of 44 patients
yielded a power of over 90% to detect moderate to strong
symptom relationships at a significance level of 5%. Gen-
erally, both staff and patients found the questionnaire
easy to complete, with questionnaire completion taking
approximately seven minutes, on average.
Patients' assessments were used to provide a comparison
with the clinicians' prevalence ranking of symptoms, and
to identify the preferred scale for assessing symptom
severity (Table 3 – see additional file 2).
Statistical analysis
SPSS v10.0 was used to analysis the data. In addition to
descriptive statistics, the analysis contained an examina-
tion of the prevalence of symptoms among the patients
with advanced tumours, and a series of multivariate anal-
yses to obtain a final set of symptoms for inclusion in the
CSS. Multi-dimensional scaling was used to examine the
relative (Euclidean) distances between symptoms, based
on clinicians' prevalence rankings. Spearman's rho corre-
lations were used to determine the relationship between
the patients' and clinicians' symptom prevalence
rankings.
Linear regression (ordinary least squares) analyses were
used to determine the most appropriate scale for assess-
ment of symptom severity (distress versus functional
impairment). Composite measures of the two scales were
constructed for all the symptoms to assess the explanatory
power of each scale, using adjusted variance (R2) for the
sample size. Data reduction analysis (principal compo-
nent) was employed using the preferred scale to identify
symptom clusters. Components required eigenvalues over
1 and were varimax rotated, to produce the best cluster fit.
Stepwise ordinary least squares regression analyses were
used to identify symptoms that were redundant within a
cluster. Composite measures of the symptoms were con-
structed for the clusters to assess the explanatory power of
each symptom, using adjusted R2s. Entry into the models
was based on a probability 0.05, and a probability of 0.10
for removal.
The project was conducted in accordance with the declara-
tion of Helsinki and was approved by the ACT Depart-
ment of Health and Community Care Human Research
Ethics Committee.
Results
Common symptoms in advanced tumours: the initial list
A list of 20 of the most common symptoms in patients
with advanced tumours was generated as described ear-
lier. The symptoms included in this list were: Lack of
energy, tiredness, lack of appetite, pain, constipation, nausea,
dry mouth, depression, anxiety, difficulty sleeping, tenseness,
vomiting, shortness of breath, lack of sexual interest, irritabil-
ity, nervousness, heartburn, dizziness, sore muscles, and numb-
ness or tingling of the hands or feet.
Prevalence rankings of symptoms by clinicians from 
around Australia
Analysis of the clinicians' prevalence rankings revealed
generally poor agreement among clinicians in the symp-
tom rankings, with a maximum of only 54% of clinicians
nominating the same ranking for a symptom (Table 2).
Nevertheless, the clinicians tended to rank symptoms in a
similar order, with the mean rankings between symptoms
being moderately well separated.
Multi-dimensional scaling supported the descriptive find-
ings, with most symptoms being ranked sequentially
according to prevalence (demonstrated in Figure 1 by the
spread and proximity of the symptoms to the horizontal
axis). The two highest ranked (most prevalent) symptoms
were lack of energy and tiredness, followed by lack of appetite
and pain while the four lowest ranked (least prevalent)
symptoms were numbness or tingling of the hands or feet, sore
muscles, dizziness and heartburn.
A second dimension was evident in the clinicians' rank-
ings (demonstrated in Figure 1 by the spread of symptoms
along the vertical axis). Physical symptoms tended to be
in the lower half of the graph while emotional symptoms
tended to be in the upper half of the graph, suggesting that
clinicians were not only focusing on symptom prevalence,
Table 2: Demographic and Clinical Characteristics of Patients in 
the Study.
Characteristic Outpatients, n = 44 (%)
Median age (range) 60 (39–81) years
Male 26 (59)
English as first language 38 (86)
ECOG performance status 0–1 30 (68)
Current Treatment(s)
Chemotherapy 29 (66)
Radiation therapy 10 (22)
Symptomatic therapy 15 (35)
Herbal medicine 3 (7)
Hormone therapy 2 (5)
Primary Tumour Site
Colorectal cancer 14 (32)
Non small cell lung cancer 5 (12)
Breast cancer 5 (12)
Small cell lung cancer 2 (5)
Non Hodgkin's lymphoma 2 (5)
CNS (glioblastoma multiforme) 2 (5)
Prostate cancer 2 (5)
Other 12 (24)BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/32
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but also the underlying cause (i.e. physical versus
emotional).
Based on the analysis of prevalence rankings and com-
ments received from clinicians, modifications were made
to the initial 20-item symptom list. First, coughing and
problems remembering things were added to the list. Second,
we agreed with comments made by clinicians that the
symptoms contained in the list should be predominantly
tumour-related. Thus, we excluded anxiety, lack of sexual
interest, nervousness and irritability, leaving a total of 18
symptoms. The exclusion of these four symptoms was not
intended to indicate they were less important, but rather
in acknowledgement that other assessment tools are avail-
able for these symptoms. Nevertheless, depression  and
tenseness were retained in the list to provide a guide to the
prevalence of emotional symptoms.
Prevalence rankings of symptoms by patients at the 
canberra hospital
The 44 outpatients at the Canberra Hospital were a diverse
group of patients with differing diagnoses. This patient
diversity was useful in examining how individual symp-
toms added to the explanation of variance within symp-
tom clusters and whether the symptom list should be
adapted further. The prevalence of symptoms reported by
the patients ranged from 64% (lack of energy) to 16%
(vomiting) (Table 3). Examining the prevalence of symp-
toms that appeared in both the initial 20-item list and the
revised 18-item list, there was a moderately strong corre-
lation between clinicians' prevalence rankings and the
prevalence of symptoms reported by the patients (Spear-
man's rho = 0.67, p = 0.005). Both clinicians and patients
agreed that lack of energy was the most prevalent, and that
numbness or tingling of the hands or feet was relatively low
in prevalence. However, examples of large disagreement
occurred for lack of appetite, constipation, difficulty sleeping,
dry mouth, tenseness and vomiting.
Severity assessment scales
In general, the results from the two severity assessment
scales were highly correlated. However, problems remem-
bering things, shortness of breath, and numbness or tingling of
the hands or feet had relatively smaller correlations
between the two scales (0.58, 0.55, and 0.57, respec-
tively). The distress severity scale explained most of the
variance for 14 of the 18 symptoms (Table 3), although
the impairment of functioning scale was more important
for heartburn, shortness of breath, weak or sore muscles and
dry mouth. As the distress severity scale explained over
90% of the variance for the majority of symptoms, the
impairment of functioning severity scale was discarded in
favour of the distress severity scale.
Symptom clusters
Using the distress severity scale, four significant symptom
clusters (components from the principal components
analysis) were found. The four symptom clusters were
Table 4: Clinicians' highest three frequencies of rankings for each symptom (percentage of clinicians giving the ranking in brackets1) and 
mean rank (SD).
Order Symptom 1st Ranking (%) 2nd Ranking (%) 3rd Ranking (%) Mean Rank (SD)
1 Lack of energy 1 (54) 2 (25) 3 (9) 2.16 (2.37)
2 Tired 1 (39) 2 (32) 3 (10) 2.56 (2.52)
3 Lack of appetite 3 (34) 2 (19) 1 (10) 3.74 (2.40)
4 Pain 3 (17) 1 (17) 4 (15) 4.22 (3.00)
5 Nausea 5 (17) 6 (14) 8 (11) 6.77 (3.39)
6 Constipation 4 (16) 6 (11) 5 (11) 7.02 (3.89)
7 Anxiety 5 (13) 4 (13) 6 (10) 7.34 (3.60)
8 Depressed 5 (14) 7 (12) 4 (9) 7.69 (3.75)
9 Difficulty sleeping 5 (12) 7 (11) 10 (10) 8.37 (3.79)
10 Shortness of breath 9 (11) 7 (10) 11 (9) 9.74 (4.16)
11 Dry mouth 5 (8) 12 (8) 6 (7) 10.17 (5.04)
12 Vomiting 8 (10) 10 (10) 13 (9) 10.20 (4.07)
13 Tense 6 (9) 13 (9) 9 (8) 10.34 (4.48)
14 Nervous 10 (9) 16 (9) 15 (8) 11.27 (4.69)
15 Lack of sexual interest 13 (10) 8 (8) 10 (8) 11.68 (5.02)
16 Irritability 14 (10) 10 (9) 11 (9) 11.76 (4.33)
17 Heartburn 17 (11) 12 (9) 15 (8) 13.12 (4.52)
18 Dizziness 18 (13) 17 (12) 15 (12) 13.96 (4.10)
19 Sore muscles 20 (21) 19 (12) 18 (11) 15.14 (4.65)
20 Numbness or tingling of the hands or feet 20 (28) 19 (18) 18 (14) 16.67 (4.01)
1. For example, looking at the distribution of rankings for lack of energy 54% of physicians ranked it as 1, 25% as 2 and 9% as 3.BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/32
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described as predominantly gastrointestinal (GI) symp-
toms (but also including pain and cognitive function),
neurological/emotional symptoms, tension, and respira-
tory symptoms. These four clusters accounted for 69% of
the variance of the varimax rotated sums of squares
loadings.
Considering these four clusters as composite measures of
the 18 symptoms, the variance explained by individual
symptoms within a cluster was reassessed. We found that
the majority of the variance in these clusters was explained
by several symptoms. For example, nausea,  constipation
and vomiting accounted for 90% of the variance in the GI/
pain/cognitive function symptom cluster, while lack of
appetite explained only 0.8% of the variance (Table 4).
Similarly, dry mouth, heartburn, numbness or tingling of the
hands or feet, depression and tiredness explained 1% or less
of the variance in their respective clusters. Hence, we
removed the six symptoms that explained little of the var-
iance within their respective clusters, reducing the 18-item
symptom list to just 12 symptoms.
We decided to exclude the tension cluster because tension
can be measured better using a psychological instrument,
leaving 11 symptoms covering the three remaining symp-
tom clusters. However, we decided to reinstate lack of appe-
tite because of its strong predictive value with respect to
survival [30]. Thus, we have recommended 12 symptoms
that explain 97.8% of the variance in the GI/pain/cogni-
tive cluster, 96.8% of the variance in the neurological/
emotional cluster, and 100% of the variance in the respi-
ratory cluster. The final 12 symptoms, contained in these
three symptom clusters (Table 5) are: Lack of energy, lack of
appetite, pain, constipation, nausea, difficulty sleeping, vomit-
ing,  shortness of breath,  dizziness,  sore muscles,  problems
remembering things and coughing.
Using these 12 symptoms, we have devised a new 12-item
symptom instrument ('The Canberra Symptom Score-
card') that incorporates a single distress severity scale.
Included is space for patients to insert up to three addi-
tional symptoms not included in the instrument. The
Canberra Symptom Scorecard is about to be assessed in
centres in Australia and overseas in patients with
Euclidean distance model showing the relative distances between symptoms in two dimensions, based on clinicians' prevalence  rankings (N = 184) Figure 1
Euclidean distance model showing the relative distances between symptoms in two dimensions, based on clinicians' prevalence 
rankings (N = 184).
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advanced (incurable) tumours receiving palliative treat-
ments. As part of this next step in the development of The
Canberra Symptom Scorecard, it will be validated against
selected existing instruments.
Discussion
The findings of this study suggest that the initial 20-item
symptom list provided a reasonable representation of the
symptoms experienced by patients with advanced
tumours (Table 1). However, the comments received from
the clinicians yielded two additional symptoms (problems
remembering things and coughing) that proved to be highly
prevalent in the patients with incurable tumours surveyed
(39% and 23% respectively). The other important sugges-
tion provided by the clinicians was to focus on physical
symptoms due to the tumour rather than emotional
Table 5: Percentage of patients that experienced each symptom and the favoured severity scale for each symptom, based on variance 
explained1 (N = 44).
Ranking Symptoms % With symptom Favoured severity scale % Variance explained
1 Lack of energy 64 Distress 92
1 Pain 64 Distress 95
3 Tiredness 59 Distress 91
4 Difficulty sleeping 46 Distress 93
5 Dry mouth 45 Functioning 95
6 Tense 43 Distress 94
7 Depression 39 Distress 98
7 Nausea 39 Distress 94
7 Problems remembering 
things
39 Distress 87
10 Shortness of breath 36 Functioning 76
10 Heartburn/belching 36 Functioning 95
12 Lack of appetite 32 Distress 97
12 Constipation 32 Distress 94
14 Dizziness 30 Distress 99
15 Weak or sore muscles 27 Functioning 99
16 Numbness or tingling of 
the hands or feet
25 Distress 81
17 Coughing 23 Distress 95
18 Vomiting 16 Distress 96
1. Variance explained refers to the adjusted R2 obtained from OLS regressions where the dependent variable was the sum of scores from the two 
severity scales (distress & function) for a symptom, and the explanatory variables were the severity scales.
Table 6: Selected results from stepwise ordinary least squares regressions showing the percentage of variance explained for each 
symptom associated with the cluster symptom measure1.
Cluster 1 GI/pain/cogn % Var Cluster 2 Neural/emot % Var Cluster 3 
Tension
% Var Cluster 4 
Respiratory
% Var
Vomiting 5.5 Difficulty sleeping 19.7 Tense 70.3 Coughing 18.9
Lack of appetite 0.8 Dizziness 66.8 Shortness of 
breath
29.7 Shortness of 
breath
81.1
Nausea 69.9 Sore/weak muscles 5.4 breath
Dry mouth 1.0 Numbness 1.0
Constipation 14.6 Depression 1.4
Heartburn 1.3 Tiredness 0.9
Pain 3.3 Lack of energy 4.9
Problems remembering things 3.7
1. A composite symptom measure was created for each of the four clusters (GI/pain/cognitive, Neurological/emotional, Tension, and Respiratory). 
The symptoms associated with each composite measure were then examined in a stepwise method for their contribution to explaining the variation 
in each cluster. The order symptoms were entered into the regression model follows the amount of variance explained, with the largest being 
entered first.BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/32
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symptoms, since other instruments assess these better.
Consequently, we reduced the list to 18 symptoms that
focused predominantly on physical problems.
The high prevalence rates for all 18 symptoms in the 44
outpatients with incurable tumours surveyed further sup-
ported the coverage (Table 2). However, these high rates
made it difficult to identify individual symptoms that
could be eliminated from the list, as we had aimed to
identify only those symptoms essential for routine
measurement.
We were able to reduce the number of symptoms further,
while maintaining good coverage, by exploring symptom
clusters. Eleven symptoms were found to explain ade-
quately the variation within the three clusters that covered
the physical symptoms (Table 4). However, we added lack
of appetite to the symptom list, making a final list of 12
symptoms. Our findings are consistent with those of
Watson et al [29] who also identified similar broad clus-
ters of physical symptoms in cancer patients, using a 30-
item version of the RSCL. We believe that these three clus-
ters (Table 5) encompass the most important symptoms
in patients with advanced tumours.
Using this final list of 12 symptoms as a guide, we reas-
sessed existing symptom assessment instruments and
found that some did not address all the symptoms we rec-
ommend (e.g. ESAS, MDASI), while others covered too
many symptoms, making them too lengthy for regular
administration (e.g. ASDS, MQOL, MSAS, RSCL). For
example, the core list of 13 symptoms of the MDASI [13]
is limited in the assessment of neurological symptoms but
contains a considerable number of symptoms related to
emotional problems. In our opinion, the usefulness of
assessing emotional (or psychological) symptoms this
way is questionable. The CSS does not include assessment
of emotional or psychological symptoms, as it concen-
trates on physical symptoms related to the tumour. If
assessment of emotional symptoms is also required, we
recommend that another suitable instrument be used.
In summary, despite a relatively large number of available
symptom assessment instruments, little research has been
undertaken to determine the adequate coverage of symp-
tom clusters appropriate for patients with advanced
tumours, and consequently the minimum list of symp-
toms needed to measure these clusters. In the present
study, we undertook such an investigation that yielded
three important symptom clusters and their associated
symptoms. Comparing our final list and existing symp-
tom lists, we found major symptoms were missing from
shorter lists most likely to be considered for routine meas-
urement in clinical practice. As a result, we recommend
that modifications need to be made to existing instru-
ments to address these limitations, and that further con-
sideration be given to issues around the measurement of
physical symptoms and psychological symptoms.
Based on our findings, we have identified a brief set of
symptoms covering the common physical symptoms
experienced by outpatients with advanced tumours. From
this we have developed a symptom assessment instru-
ment called 'The Canberra Symptom Scorecard' (CSS) that
comprehensively covers the important and common
symptoms associated with advanced (incurable) tumours.
We believe that this instrument should help clinicians to
monitor these symptoms in outpatients undergoing palli-
ative treatment(s), such as palliative chemotherapy, palli-
ative radiotherapy or symptomatic treatments. It is about
to be assessed in patients with advanced tumours receiv-
ing palliative treatments in centres in Australia and over-
seas, and, as part of this assessment, it will be validated
against existing instruments. We believe that this investi-
gation should establish the validity and usefulness of the
CSS in patients with advanced tumours receiving pallia-
tive treatments aimed at improving patients' symptoms.
Conclusions
We reviewed existing symptom assessment instruments
and found a number of deficiencies such as existing
instruments being too long or burdensome, too short, or
measuring quality of life, rather than tumour-related
physical symptoms. Others sacrificed important physical
symptoms for emotional symptoms that may be assessed
better using psychological instruments. Therefore, we
devised a new symptom instrument ("The Canberra
Symptom Scorecard", (CSS)). This is a short 12-item
symptom questionnaire that focuses on the physical
symptoms important in patients with advanced tumours.
It appears suitable for outpatients with advanced (incura-
Table 7: Symptom clusters and symptoms in the canberra 
symptom scorecard
Symptom Cluster Symptoms
GI/pain/cognitive 1 Nausea
2 Constipation
3 Vomiting
4 Lack of appetite
5 Pain
6 Problems remembering things
Neurological 7 Dizziness
8 Problems sleeping
9 Weak or sore muscles
10 Lack of energy
Respiratory 11 Shortness of breath
12 CoughingBMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/32
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ble) tumours receiving palliative treatments and is about
to be assessed in such patients, both in Australia and over-
seas when it will also be validated against existing
instruments.
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